Respiratory Drug Delivery Formulation Market - Drug delivery to the lungs: challenges and opportunities Analysis, 2021 – 2026
Global Respiratory Drug Delivery Formulation Market Analysis
Overview
Various respiratory disorders are treated with respiratory medication delivery formulations. In recent years, the pulmonary route of drug administration has shown to be the most successful for the treatment of respiratory disorders since it allows for direct drug administration to the lungs for both local and systemic therapy. Inhalers and capsules are examples of medication delivery methods used in the respiratory system. The compositions can also be taken orally or by the nose. Dry powder, solution aerosol, and suspension aerosol are the three types of respiratory medication delivery formulations. A wide range of pharmaceutical medications are delivered to the lungs using metered dosage inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. Cystic fibrosis, chronic obstructive pulmonary illness, and asthma are all treated using breathing drug delivery formulations.
Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2649
Drivers
Asthma affects almost 334 million people globally, according to the Global Asthma Network, therefore, a growth in the frequency and incidence of respiratory disorders has resulted in an increase in demand for respiratory medication delivery formulations. Healthcare companies are focusing on expanding access to cheap drugs to give patients and pharmacists with new alternatives, therefore addressing the scarcity of respiratory drug delivery formulations, which is estimated to boost growth of the global respiratory drug delivery formulation market. Teva Pharmaceuticals reported in August 2017 that the US FDA had authorized its QVAR RediHaler inhalation aerosol for the sustained treatment of asthma in patients aged 4 years and older as a preventive medication. Teva Pharmaceuticals also gained FDA certification for its ProAir Digihaler device, a virtual inhaler that utilizes sensors to link to a mobile app, in December 2018. It is used to treat bronchospasm in individuals who have reversible obstructive pulmonary disease.
In addition, the increased incidence of different infectious disorders, such as respiratory tract infections, is estimated to propel the respiratory drug delivery formulation market forward in the near future. In 2016, India had around 55.3 million cases of chronic obstructive pulmonary disease, according to a research published in the Lancet Global Health Journal.
Tailored Information as per niche requirement:
LIMITED TIME OFFER - Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2649
Furthermore, the global respiratory drug delivery formulation market is being boosted by a growing number of initiatives conducted by both government and non-government groups. The National Asthma Control Program (NACP) of the Centers for Disease Control and Prevention (CDC) offers grants to educate asthma sufferers. As a result of these measures, more people are becoming aware of asthma, which is projected to lead to an increase in the use of pulmonary medication delivery systems to treat asthma and chronic obstructive lung disease.
Restraints
The market's expansion is likely to be limited by strict regulatory constraints, drug patent expiration, and challenges associated to drug stability.
Regional Analysis
Due to the high incidence and prevalence of asthma, ongoing government attempts to decrease the cost of treatment, and a growth in the elderly population in the U.S., North America is projected to have a leading position in the global respiratory drug delivery formulation market throughout the projected period.
Moreover, the region's respiratory drug delivery formulation market is positioned to gain from the presence of significant pharmaceutical firms, an ageing population, modern healthcare infrastructure, high disposable income, and lifestyle changes. 3M medication delivery systems released the 3M intelligent control inhaler in November 2017, which is a fully integrated device that provides precise doses to patients.
To get detailed table of content (ToC), please click - https://www.coherentmarketinsights.com/ongoing-insight/toc/2649
Competitive Landscape
Major companies contributing in the global respiratory drug delivery formulation market are Omron Corporation, Merck and Co., Inc., AstraZeneca plc. 3M, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Aphios Corporation, Catalent Pharma Solutions, Hovione, Sunovion Pharmaceuticals Inc., Boehringer Ingelheim GmbH, and Novartis AG.
Companies are concentrating their efforts on the research, production, and marketing of multisource and branded medications, which is boosting growth of the global respiratory drug delivery formulation market. AstraZeneca announced in November 2017 that the US Food and Drug Administration (FDA) has authorized Fasenra (benralizumab) for the treatment of severe asthma patients aged 12 and above.
Table of Content
Global Respiratory Drug Delivery Formulation Market Research Report
Section 1: Global Respiratory Drug Delivery Formulation Industry Overview
Section 2: Global Economic Impact on Respiratory Drug Delivery Formulation Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Respiratory Drug Delivery Formulation Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Respiratory Drug Delivery Formulation Market Forecast
Other Related Reports:
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- Coherent Market Insights
-
Name:
- Nirav Gokani
- Email:
-
Telephone:
- +918849480752
- Website:
